Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Investors with a lot of money to spend have taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the positions showed up on publicly ...

London: Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...

RAHWAY, N.J., August 29, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630.

Tuvusertib is under clinical development by Merck and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) ...

MK-5720 is under clinical development by Merck and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) ...

Merck & Co's Keytruda is poised to move even ... reduced death or disease recurrence by 24% compared to placebo when used as adjuvant therapy after surgery in an all-comer NSCLC population ...

Merck (NYSE:MRK) shares snapped six straight sessions of gains, as the stock closed 0.28% lower at $116.27 on Monday. The New Jersey based healthcare giant gained 2.58% in the preceding six ...

RAHWAY, N.J. - Merck & Co., Inc., also known as MSD outside the United ... This approval marks the introduction of the first activin signaling inhibitor therapy in the European Union, Iceland, ...

RAHWAY, N.J. - Merck & Co., Inc., also known as MSD outside ... This approval marks the introduction of the first activin signaling inhibitor therapy in the European Union, Iceland, Liechtenstein ...